Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSP-CAR30 in CD30+ Lymphomas
NCT04653649Phase 2Unknown
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Sep 2020
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous CD30.CAR-T in Hodgkin lymphoma (HL) and T-cell lymphoma, sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: Safety and toxicity of the administration of autologous anti-CD30 CAR T-cells at 12 months, Maximum Tolerated Dose at 12 months and 1 more. Status: unknown.
02
Drugs
autologous CD30.CAR-T
03
Conditions
Hodgkin lymphoma (HL)T-cell lymphoma
Beyond the preview
Go deeper on NCT04653649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653649.